Patrick: An Introduction to Medicinal Chemistry 4e
Chapter 13
Further reading
Acharya, K. R., et al. (2003) ACE revisited: a new target for structure-based drug design. Nature Reviews Drug Discovery, 2, 891-902 [DOI: 10.1038/nrd1227] [PubMed: 14668810].
Bolin, J. T., Filman, D. J., Matthews, D. A., Hamlin, R. C., and Kraut, J. (1982) Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 Å resolution. I. General features and binding of methotrexate. Journal of Biological Chemistry, 257, 13650-13662 [PubMed: 6815178] (methotrexate binding).
Hruby, V. J. (2002) Designing peptide receptor agonists and antagonists. Nature Reviews Drug Discovery, 1, 847-858 [DOI: 10.1038/nrd939] [PubMed: 12415245].
Jeffrey, G. A. (1991) Hydrogen bonding in biological structures. Springer-Verlag, New York.
Khan, A. R., et al. (1998) Lowering the entropic barrier for binding conformationally flexible inhibitors to enzymes. Biochemistry, 37, 16839-16845 [DOI: 10.1021/bi9821364] [PubMed: 9836576].
Luca, S., et al. (2003) The conformation of neurotensin bound to its G protein-coupled receptor. Proceedings of the National Academy of Sciences of the USA, 100, 10706-10711 [DOI: 10.1073/pnas.1834523100] [PubMed: 12960362] (active conformation by NMR).
Meyer, E. G., et al. (1995) Backward binding and other structural surprises. Perspectives in Drug Discovery and Design, 3, 168-195 [DOI: 10.1007/BF02174473].
Pellecchia, M., Sem, D. S., and Wuthrich, K. (2002) NMR in drug discovery. Nature Reviews Drug Discovery, 1, 211-219 [DOI: 10.1038/nrd748] [PubMed: 12120505].


